Kenneth Erland Johnson - Jan 3, 2025 Form 4 Insider Report for Xeris Biopharma Holdings, Inc. (XERS)

Role
Senior Vice President, Global Development and Medical Affairs
Signature
/s/ Beth Hecht, Attorney-in-Fact
Stock symbol
XERS
Transactions as of
Jan 3, 2025
Transactions value $
-$44,768
Form type
4
Date filed
1/7/2025, 04:42 PM
Previous filing
Jan 31, 2024
Next filing
Feb 3, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XERS Common Stock Tax liability -$44.8K -12.4K -3.31% $3.61 362K Jan 3, 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of Restricted Stock Units vested as of January 3, 2025.
F2 Includes 1,129 shares acquired on December 31, 2024 under the Xeris Pharmaceuticals, Inc. 2018 Employee Stock Purchase Plan, as amended.

Remarks:

Senior Vice President, Global Development and Medical Affairs